TL;DR: Semaglutide (GLP-1 only) offers the most trial data and lowest cost; tirzepatide (GLP-1+GIP) balances stronger average results with FDA approval; retatrutide (GLP-1+GIP+glucagon) shows the highest reported weight loss in Phase 2 trials but remains investigational. This guide compares mechanisms, dosing, and side effects side by side.
The field of incretin-based peptides has evolved rapidly, from single-receptor GLP-1 agonists to dual and now triple-receptor agonists. This guide compares the three major players: Semaglutide, Tirzepatide, and Retatrutide.
Quick Comparison
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptors | GLP-1 | GIP + GLP-1 | GIP + GLP-1 + Glucagon |
| Generation | 1st | 2nd | 3rd |
| Frequency | Once weekly | Once weekly | Once weekly |
| Max Dose | 2.4mg | 15mg | 12mg |
| Trial Weight Loss | ~15-17% | ~20-22% | ~24% |
| FDA Status | Approved | Approved | Phase 3 |
Mechanism of Action
Semaglutide: The GLP-1 Pioneer
Semaglutide is a selective GLP-1 receptor agonist with 94% homology to native GLP-1. For background on this compound, see What Is Semaglutide?
How it works:
- Binds to GLP-1 receptors in pancreas, brain, and GI tract
- Stimulates glucose-dependent insulin secretion
- Suppresses glucagon release
- Delays gastric emptying
- Activates satiety centers in hypothalamus
Key advantage: Extensive clinical data, well-established safety profile.
Tirzepatide: The Dual Agonist
Tirzepatide targets both GIP and GLP-1 receptors, the first approved dual incretin. See What Is Tirzepatide? for a deeper mechanism overview.
How it works:
- GLP-1 activation provides appetite suppression and glycemic control
- GIP activation enhances insulin secretion and may affect adipose tissue
- Synergistic effects between both pathways
- Potential for enhanced beta-cell function
Key advantage: Superior efficacy to GLP-1 alone with dual mechanism.
Retatrutide: The Triple Threat
Retatrutide adds glucagon receptor activation to the GIP/GLP-1 combination. Read What Is Retatrutide? for a closer look at this investigational compound.
How it works:
- GLP-1 and GIP pathways (same as tirzepatide)
- Glucagon receptor activation increases energy expenditure
- Enhanced lipid oxidation and fat mobilization
- Potential hepatic benefits from glucagon signaling
Key advantage: Highest efficacy observed in trials, novel triple mechanism.
Receptor Binding Comparison
| Receptor | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| GLP-1 | ✓✓✓ (primary) | ✓✓ | ✓✓ |
| GIP | ✗ | ✓✓✓ (primary) | ✓✓ |
| Glucagon | ✗ | ✗ | ✓✓ |
Clinical Trial Results
Weight Loss Outcomes
| Peptide | Trial | Duration | Max Dose | Mean Weight Loss |
|---|---|---|---|---|
| Semaglutide | STEP 1 | 68 weeks | 2.4mg | -14.9% |
| Semaglutide | STEP 2 | 68 weeks | 2.4mg | -9.6% (T2D) |
| Tirzepatide | SURMOUNT-1 | 72 weeks | 15mg | -20.9% |
| Tirzepatide | SURMOUNT-2 | 72 weeks | 15mg | -14.7% (T2D) |
| Retatrutide | Phase 2 | 48 weeks | 12mg | -24.2% |
STEP 1, SURMOUNT-1, and Retatrutide Phase 2. Not head-to-head; populations and durations differ.
Note: Direct comparison is limited as trials had different designs and populations.
Response Rates
Percentage achieving ≥5% weight loss:
| Peptide | ≥5% Loss | ≥10% Loss | ≥15% Loss | ≥20% Loss |
|---|---|---|---|---|
| Semaglutide 2.4mg | 86% | 69% | 50% | 32% |
| Tirzepatide 15mg | 91% | 79% | 66% | 50% |
| Retatrutide 12mg | 93% | 87% | 77% | 63% |
Higher curves = more responders at deeper loss thresholds.
Dosing Protocols
Semaglutide
| Week | Dose | Notes |
|---|---|---|
| 1-4 | 0.25mg | Initial titration |
| 5-8 | 0.5mg | First escalation |
| 9-12 | 1.0mg | Second escalation |
| 13-16 | 1.7mg | Third escalation |
| 17+ | 2.4mg | Maintenance |
Titration: 4 weeks per dose level
Tirzepatide
| Week | Dose | Notes |
|---|---|---|
| 1-4 | 2.5mg | Initial titration |
| 5-8 | 5mg | First escalation |
| 9-12 | 7.5mg | Second escalation |
| 13-16 | 10mg | Third escalation |
| 17-20 | 12.5mg | Fourth escalation |
| 21+ | 15mg | Maximum |
Titration: 4 weeks per dose level
Retatrutide
| Week | Dose | Notes |
|---|---|---|
| 1-4 | 1mg | Initial titration |
| 5-8 | 2mg | First escalation |
| 9-12 | 4mg | Second escalation |
| 13-16 | 8mg | Third escalation |
| 17+ | 12mg | Maximum |
Titration: 4 weeks per dose level
Side Effect Comparison
GI Side Effects (Most Common)
| Side Effect | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Nausea | 44% | 31% | 35% |
| Diarrhea | 30% | 23% | 22% |
| Vomiting | 24% | 12% | 16% |
| Constipation | 24% | 17% | 15% |
Note: GI side effects typically decrease with continued use and proper titration.
Other Considerations
| Factor | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Injection site reactions | Low | Low | Low |
| Heart rate increase | Mild | Mild | Mild |
| Hypoglycemia risk (alone) | Very low | Very low | Very low |
Reconstitution & Storage
All three peptides share similar handling requirements — see our peptide reconstitution guide for detailed step-by-step practices:
| Parameter | Recommendation |
|---|---|
| Reconstitution | Bacteriostatic water |
| Storage (lyophilized) | -20°C, 2+ years |
| Storage (reconstituted) | 2-8°C, 4-6 weeks |
| Injection route | Subcutaneous |
| Frequency | Once weekly |
Cost Considerations (Research Grade)
Approximate costs for research peptides:
| Peptide | 5mg Vial | 10mg Vial | Cost/Week (Maintenance) |
|---|---|---|---|
| Semaglutide | $$ | $$$ | $$ (at 2.4mg) |
| Tirzepatide | $$$ | $$$$ | $$$$ (at 15mg) |
| Retatrutide | $$$$ | $$$$$ | $$$$ (at 12mg) |
Note: Tirzepatide and Retatrutide require higher mg doses, affecting weekly cost.
Which to Choose?
Consider Semaglutide If:
- Extensive safety data is priority
- Budget is a consideration
- Proven track record matters
- GLP-1-only mechanism is sufficient
Consider Tirzepatide If:
- Enhanced efficacy is desired
- Dual mechanism benefits appeal
- Budget allows for higher cost
- FDA-approved status preferred
Researchers moving between compounds may also find our guide to switching from semaglutide to tirzepatide useful for planning a transition.
Consider Retatrutide If:
- Maximum efficacy is the goal
- Novel mechanisms are of interest
- Willing to use pre-approval compound
- Research is focused on cutting-edge peptides
Stacking Considerations
These peptides should generally NOT be combined:
- Overlapping mechanisms increase side effects
- No established protocols for combinations
- Redundant receptor activation
Instead, consider complementary peptides:
- Healing peptides (BPC-157, TB-500) — see our BPC-157 vs TB-500 comparison
- GH secretagogues (if appropriate)
- Other non-overlapping compounds
Future Outlook
| Peptide | Status | What’s Next |
|---|---|---|
| Semaglutide | Mature | Oral formulations, new indications |
| Tirzepatide | Growing | Additional approvals, more data |
| Retatrutide | Emerging | Phase 3 results, potential approval |
The field continues to evolve, with potential quad-agonists and other novel approaches in development.
Summary
| Factor | Winner |
|---|---|
| Most Data | Semaglutide |
| Best Efficacy | Retatrutide |
| Balanced Choice | Tirzepatide |
| Most Accessible | Semaglutide |
| Innovation | Retatrutide |
Each peptide offers distinct advantages. The choice depends on research objectives, budget, and risk tolerance regarding newer compounds.
FAQ
How do semaglutide, tirzepatide, and retatrutide mechanistically differ?
Semaglutide activates only the GLP-1 receptor. Tirzepatide adds GIP receptor activation for a dual mechanism, and retatrutide layers in glucagon receptor activity for a triple mechanism. Each additional receptor pathway is associated with progressively higher average weight-loss figures in trials, though comparisons are not head-to-head.
Is retatrutide approved for use?
No. As of the trial data available through 2026, retatrutide remains in Phase 3 development and is not FDA-approved. It is studied strictly as a research compound, and researchers should treat any retatrutide material as investigational rather than a finished pharmaceutical product.
Can these three peptides be combined in a research protocol?
Generally no. Semaglutide, tirzepatide, and retatrutide share overlapping GLP-1 receptor activity, so stacking them increases redundant signaling and side-effect risk without established dosing protocols. Researchers exploring combination approaches typically look at non-overlapping compounds instead, such as healing or metabolic peptides.
Why does trial weight loss increase from semaglutide to retatrutide?
Each successive compound adds a receptor pathway: GIP alongside GLP-1 in tirzepatide, then glucagon receptor activation in retatrutide. Glucagon signaling is linked to increased energy expenditure and fat oxidation, which may explain the higher mean weight-loss percentages recorded in retatrutide’s Phase 2 trial data.
Which peptide is most cost-effective for research budgets?
Semaglutide is typically the least expensive option since its maintenance dose (2.4mg) is lower than tirzepatide’s or retatrutide’s effective ranges. Tirzepatide and retatrutide both require higher milligram quantities per dose, which increases weekly research costs even before accounting for per-mg pricing differences.
Last updated: December 21, 2025
Disclaimer: This information is for educational and research purposes only. These peptides are research chemicals and/or prescription medications. Always follow applicable laws and regulations.